4.8 Article

Potent inhibition of microRNA in vivo without degradation

Journal

NUCLEIC ACIDS RESEARCH
Volume 37, Issue 1, Pages 70-77

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/nar/gkn904

Keywords

-

Funding

  1. National Institutes of Health [R43 AI072802]
  2. Regulus Therapeutics
  3. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI072802] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Chemically modified antisense oligonucleotides (ASOs) are widely used as a tool to functionalize microRNAs (miRNAs). Reduction of miRNA level after ASO inhibition is commonly reported to show efficacy. Whether this is the most relevant endpoint for measuring miRNA inhibition has not been adequately addressed in the field although it has important implications for evaluating miRNA targeting studies. Using a novel approach to quantitate miRNA levels in the presence of excess ASO, we have discovered that the outcome of miRNA inhibition can vary depending on the chemical modification of the ASO. Although some miRNA inhibitors cause a decrease in mature miRNA levels, we have identified a novel 2-fluoro/2-methoxyethyl modified ASO motif with dramatically improved in vivo potency which does not. These studies show there are multiple mechanisms of miRNA inhibition by ASOs and that evaluation of secondary endpoints is crucial for interpreting miRNA inhibition studies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available